Biodel shares should move higher ahead of insulin trial results in the third quarter.
One trader believes Rockwell shares will rise into clinical trial results expected in July.
The market overreacted to the resignation of Synta's R&D chief.
Ziopharm is an example of a stock with clinical trial results that can be traded realtively safely.
Three factors that will cause Dynavax shares to gain as get closer to the approval of its Hep B vaccine.
I expect traders will get an opportunity to profit from increased focus on Titan through March.
Look at A.P. Pharma as a trade, not as a long-term investment, says trader Mark Messier.
Alexza is setting up as a classic biotech run-down stock, says trader Mark Messier.
Anacor will be releasing phase III results for a toenail fungus drug in January.
FDA expected to issue approval decision on orphan drug Ravicti on Jan. 23.